Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 6
2008 1
2009 2
2010 2
2011 1
2012 3
2013 5
2014 6
2015 15
2016 17
2017 11
2018 20
2019 25
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

116 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S. Han X, et al. J Med Chem. 2019 Jan 24;62(2):941-964. doi: 10.1021/acs.jmedchem.8b01631. Epub 2019 Jan 10. J Med Chem. 2019. PMID: 30629437
The BUB3-BUB1 Complex Promotes Telomere DNA Replication.
Li F, Kim H, Ji Z, Zhang T, Chen B, Ge Y, Hu Y, Feng X, Han X, Xu H, Zhang Y, Yu H, Liu D, Ma W, Songyang Z. Li F, et al. Among authors: han x. Mol Cell. 2018 May 3;70(3):395-407.e4. doi: 10.1016/j.molcel.2018.03.032. Mol Cell. 2018. PMID: 29727616 Free PMC article.
The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development.
Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, Collins RH, Xiao X, You MJ, Zhang CC. Kang X, et al. Among authors: han x. Nat Cell Biol. 2015 May;17(5):665-77. doi: 10.1038/ncb3158. Epub 2015 Apr 27. Nat Cell Biol. 2015. PMID: 25915125 Free PMC article.
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X, Zhao L, Xiang W, Qin C, Miao B, Xu T, Wang M, Yang CY, Chinnaswamy K, Stuckey J, Wang S. Han X, et al. J Med Chem. 2019 Dec 26;62(24):11218-11231. doi: 10.1021/acs.jmedchem.9b01393. Epub 2019 Dec 5. J Med Chem. 2019. PMID: 31804827
Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials.
Zheng X, Zhao X, Xu H, Han X, Xu H, Dong X, Peng R, Yang L, Wei Q, Ai J. Zheng X, et al. Among authors: han x. Medicine (Baltimore). 2019 Nov;98(44):e17748. doi: 10.1097/MD.0000000000017748. Medicine (Baltimore). 2019. PMID: 31689828 Free PMC article.
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, Yang CY, Wang M, Han X, Wang S. Li Y, et al. Among authors: han x. J Med Chem. 2019 Jan 24;62(2):448-466. doi: 10.1021/acs.jmedchem.8b00909. Epub 2018 Dec 10. J Med Chem. 2019. PMID: 30525597 Free PMC article.
Cellular response to moderate chromatin architectural defects promotes longevity.
Yu R, Sun L, Sun Y, Han X, Qin L, Dang W. Yu R, et al. Among authors: han x. Sci Adv. 2019 Jul 10;5(7):eaav1165. doi: 10.1126/sciadv.aav1165. eCollection 2019 Jul. Sci Adv. 2019. PMID: 31309140 Free PMC article.
Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
Wang W, Li N, Li X, Tran MK, Han X, Chen J. Wang W, et al. Among authors: han x. Cell Rep. 2015 Oct 20;13(3):524-532. doi: 10.1016/j.celrep.2015.09.014. Epub 2015 Oct 8. Cell Rep. 2015. PMID: 26456820 Free PMC article.
The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis: A systematic review and meta-analysis.
Lu W, Ren C, Han X, Yang X, Cao Y, Huang B. Lu W, et al. Among authors: han x. Medicine (Baltimore). 2018 Sep;97(37):e12325. doi: 10.1097/MD.0000000000012325. Medicine (Baltimore). 2018. PMID: 30212979 Free PMC article. Review.
116 results
Jump to page